



King's Research Portal

DOI:

[10.1016/S2215-0366\(21\)00046-8](https://doi.org/10.1016/S2215-0366(21)00046-8)

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

De Picker , L. J., Vai, B., Casanova Dias , M., Branchi , I., Benedetti, F., Benros , M. E., Borsini, A., Leza , J. C., Kärkkäinen, H., Männikkö, M., Pariante, C. M., Sönmez Güngör , E., Szczegielniak , A., Tamouza , R., van der Markt, A., Fusar-Poli, P., Beezhold , J., & Leboyer , M. (2021). Severe mental illness and European COVID-19 vaccination strategies. *The Lancet Psychiatry*, 8(5), 356-359. [https://doi.org/10.1016/S2215-0366\(21\)00046-8](https://doi.org/10.1016/S2215-0366(21)00046-8)

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Title: Severe mental illness and European COVID-19 vaccination strategies

Livia J. De Picker MD PhD^{a,b*}, Marisa Casanova Dias MRCPsych MSc^{c,d}, Michael E. Benros MD PhD^{e,f}, Benedetta Vai PhD^{g,h}, Igor Branchi PhDⁱ, Francesco Benedetti MD PhD^{g,j}, Alessandra Borsini PhD^k, Juan Carlos Leza MD PhD^l, Hilikka Kärkkäinen BSocSc^m, Miia Männikkö MSocScⁿ, Carmine M. Pariante MD PhD^k, Ekin Sönmez Güngör MD^o, Anna Szczegieliński MD^p, Ryad Tamouza MD PhD^{q,r,s}, Afra van der Markt MD^t, Paolo Fusar-Poli MD PhD^{u,v}, Julian Beezhold MBChB FRCPsych^{w,x}, Marion Leboyer MD PhD^{q,r,s}

Affiliations :

- a. University Psychiatric Hospital Campus Duffel, Duffel, Belgium. Email: livia.depicker@emmaus.be
- b. Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium. Email: livia.depicker@uantwerp.be
- c. National Centre for Mental Health, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University. Email: casanovadiasm@cardiff.ac.uk
- d. Section of Women's Mental Health, Institute of Psychiatry, Psychology and Neurosciences, King's College London
- e. Copenhagen Research Centre for Mental Health, Copenhagen University Hospital, Denmark. Email: Michael.Eriksen.Benros@regionh.dk
- f. Department of Immunology & Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- g. Psychiatry & Clinical Psychology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milano, Italy. Email: vai.benedetta@hsr.it; benedetti.francesco@hsr.it
- h. Fondazione Centro San Raffaele, Italy
- i. Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy. Email: igor.branchi@iss.it
- j. University Vita-Salute San Raffaele, Milano, Italy
- k. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom. Email: alessandra.borsini@kcl.ac.uk; carmine.pariante@kcl.ac.uk
- l. Department of Pharmacology & Toxicology, Faculty of Medicine, Universidad Complutense Madrid, CIBERSAM, Imas12, IUINQ. Madrid, Spain. Email: jcleza@med.ucm.es
- m. Global Alliance of Mental Illness Advocacy Networks-Europe. Email: hilkkakarkkainen@gmail.com
- n. European Federation of Associations of Families of People with Mental Illness. Email: miia.mannikko@hotmail.com
- o. University of Health Sciences, Erenköy Mental Health and Neurological Diseases Training and Research Hospital, Istanbul, Turkey. Email: ekinonmez88@gmail.com
- p. Department of Psychiatric Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland. Email: anna.szczegieliński@gmail.com
- q. Université Paris Est Creteil (UPEC), Inserm U 955, IMRB Translational Neuropsychiatry Lab, F-94010 Creteil, France. Email : tamouza.ryad@gmail.com; marion.leboyer@inserm.fr
- r. AP-HP, Hôpitaux Universitaires H. Mondor, DMU IMPACT, FHU ADAPT, F-94010, Créteil, France
- s. Fondation FondaMental, Creteil, France
- t. Amsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry, Amsterdam Public Health Research Institute, The Netherlands. Email: a.vandermarkt@ggzingeest.nl
- u. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom. Email: paolo.fusar-poli@kcl.ac.uk
- v. Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
- w. Norwich Medical School, University of East Anglia, United Kingdom. Email: j.beezhold@uea.ac.uk
- x. Mental Health Liaison Service, Norfolk and Norwich University Hospital, Norfolk and Suffolk NHS Foundation Trust, Norwich, United Kingdom

*Corresponding author : livia.depicker@uantwerp.be; +32 15 30 38 47

Postal address:

Wetenschappelijk Onderzoek t.a.v. Livia De Picker
UPC Duffel
Stationsstraat 22c
2570 Duffel
Belgium

Keywords: COVID-19; SARS-CoV-2; vaccine; vaccination; severe mental illness; schizophrenia; mental health policy; psychiatry; Europe

Word count: 803w

The European Union advises prioritising for vaccination “persons whose state of health makes them particularly at risk” for severe COVID-19, but leaves it to member states to decide which medical conditions to prioritise. Ethical, neuroscientific, and public health considerations have been emphasized to prioritise individuals with severe mental illness (i.e., psychotic disorders, bipolar disorders, and severe major depressive disorders).¹⁻³ We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countries (cfr. Appendix).

Eight of 20 countries’ national vaccine strategy documents explicitly mentioned psychiatry or mental illness. Several countries prioritised institutional residents, which may include severe mental illness (Table 1). Only four countries (Denmark, Germany, the Netherlands, and the UK) had some form of higher vaccination priority for outpatients with severe mental illness. Additionally, Latvia, Romania, Spain, and Sweden prioritised outpatients with disabilities, possibly including severe mental illness, whereas the Czech Republic and Sweden stipulated behavioural or mental problems possibly hindering pandemic regulation adherence as priority indication.

A European Centre for Disease Control and Prevention survey found most European countries used a combination of epidemiological data, mathematical modelling, guidelines, ethical considerations, and published research findings to define specific morbidities for vaccine prioritisation.⁴

Examples of approaches with positive outcomes for severe mental illness include:

The UK used an Oxford University evidence-based algorithm to calculate the number of vaccinations needed to prevent one death.⁵ Importantly, this QCovid® algorithm (<https://qcovid.org/>; Copyright © 2020, University of Oxford), based on April-June 2020 UK data, explicitly includes severe mental illness among its risk predictors, and so does the UK vaccination strategy.. Preliminary data however indicate vaccination coverage for patients with severe mental illness is lagging behind that of other co-morbidity groups.⁶

Denmark and the Netherlands initially omitted mental disorders from their COVID-19 vaccination strategies. After a large nationwide cohort study found that severe mental illness and use of antipsychotics were associated with an increased risk for 30-day mortality (adjusted OR 2.5; 95%CI 1.2-5.1 and 3.3; 95%CI 2.3-4.8, respectively),⁷ the Danish Health Authority urged healthcare practitioners to refer for priority vaccination patients with psychotic disorders and other individuals with complex severe mental illness deemed to be at particular high risk by the treating physician. The Netherlands increased prioritisation of severe mental illness patients following advocacy from mental health associations.⁸

The German federal research institute performed an “umbrella review” of published systematic reviews and meta-analyses to inform the federal ministry of health’s selection of risk comorbidities.⁹ However, evidence on psychiatric morbidity had not yet been systematically summarized at that time and was therefore not included in the resulting strategy. Following a recent update of its literature review, in which severe mental illness was found to be one of the few medical comorbidities with OR >2.0 for COVID-19 hospitalisation and mortality, the strategy now explicitly includes severe mental illness in the highest risk group of medical comorbidities.⁹

Multiple high-quality studies have demonstrated odds ratios for comorbid severe mental illness, and schizophrenia in particular, to equal or even surpass those of other risk comorbidities included for prioritisation (Table 1).^{7,10} Evidence-based policy would then require severe mental illness be included in the list of risk comorbidities. Yet several sources of bias may have caused the risks associated with severe mental illness to be overlooked by most countries. Firstly, mental disorders are often not included as predictors in COVID-19 outcome studies. Secondly, studies specifically investigating the risks of psychiatric comorbidity were not yet summarized in systematic reviews or meta-analyses and therefore ignored by some national strategies and mathematical models.

In summary, there is a compelling medical, ethical, and economic case for targeted early vaccination for the vulnerable group of patients with severe mental illness. Our joint recommendations, representing professionals, patients, and families, are clear and urgent: (1) explicit inclusion of both inpatients and outpatients with severe mental illness in medical priority groups for COVID-19 vaccination, (2) meaningful patient- and family organisational participation in developing vaccination plans, and (3) engagement of peer workers in providing vaccination education to patients.

European countries’ vaccination strategies try to balance ethical and scientific evidence, but for individuals with severe mental illness an evidence-policy disconnect remains. Most of these patients are treated in the community,

yet these individuals are overlooked by the majority of European COVID-19 vaccination strategies. Information collected in this report is not definitive or exhaustive. Countries are still developing vaccination plans and strategies may change as knowledge evolves. EU member states have been asked to share best practices for prioritisation through the Health Security Committee, coordinated by the European Commission.

We therefore call on the European authorities (Council, Parliament and Commission), as well as national health authorities and the scientific community to take note of the summarized evidence and recommendations outlined in this paper, and to correct this intolerable inequality.

References

1. De Hert M, Mazereel V, Detraux J, Van Assche K. Prioritizing COVID-19 vaccination for people with severe mental illness. *World Psychiatry* 2021; **20**(1):54-55.
2. De Picker LJ, Yolken R, Benedetti F, et al. Viewpoint | European COVID-19 exit strategy for people with severe mental disorders: too little, but not yet too late. *Brain, Behavior, and Immunity* 2021. doi: 10.1016/j.bbi.2021.01.008
3. Warren N, Kisely S, Siskind D. Maximizing the Uptake of a COVID-19 Vaccine in People With Severe Mental Illness: A Public Health Priority. *JAMA Psychiatry* 2020. doi: 10.1001/jamapsychiatry.2020.4396
4. European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK – 2 December 2020. Stockholm: ECDC; 2020. URL: <https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines> (accessed Jan 14th, 2021).
5. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* 2020; **371**: m3731.
6. MacKenna B, Curtis HJ, Morton CE, et al. Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY. medRxiv 2021: 2021.01.25.21250356. [preprint]
7. Reilev M, Kristensen KB, Pottegard A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. *Int J Epidemiol* 2020; **49**(5): 1468-81.
8. De Jonge H, Nederlands Ministerie van Volksgezondheid, Welzijn en Sport. COVID-19 vaccinatiestrategie update stand van zaken. Parnassusplein 5, 2511 VX Den Haag, the Netherlands; 2021. <https://www.rijksoverheid.nl/documenten/kamerstukken/2021/01/04/kamerbrief-over-covid-19-vaccinatiestrategie-update-stand-van-zaken> (accessed Jan 7th, 2021).
9. Robert Koch Institut. Beschluss der STIKO zur 2. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung. 2021. *Epidemiologisches Bulletin* 5/2021. URL: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/05_21.pdf (accessed Feb 3rd, 2021).
10. Nemani K, Li C, Olfson M, et al. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. *JAMA Psychiatry* 2021. doi:10.1001/jamapsychiatry.2020.4442

Acknowledgements

This paper has been developed collaboratively and has received endorsements from the most prominent European psychiatric associations: (in alphabetical order) the European College of Neuropsychopharmacology (ECNP), the European Psychiatric Association (EPA), the European Federation of Associations of Families of People with Mental Illness (EUFAMI), the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Union of Medical Specialists Section of Psychiatry (UEMS-Psychiatry).

The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic Paula Mustonen (Finland), Jördis Rausch (Germany), Thanos Khanellopoulos (Greece), Zetti Azvee (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Bajouco (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellstenius and Tove Mogren (Sweden).

Funding and conflict of interest

No specific funding was received for the current work. Several authors are involved in international psychiatric associations (see Appendix). Other than this, the authors report no conflict of interest related to the current work. Dr. De Picker reports research grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. Dr. Fusar Poli reports personal fees from Menarini, personal fees from Angelini, personal fees from Lundbeck, outside the submitted work. Professor Leboyer reports personal fees from Janssen, personal fees from Sanofi, educational grants from Otsuka and Lundbeck, and research grants from Roche, all outside the submitted work. Professor Pariante has received research and consultancy funding from Johnson & Johnson and Boehringer Ingelheim; moreover, Professor Pariante is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer; all outside the submitted work. Professor Pariante is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, and by a NIHR Senior Investigator. Co-authors MEB, BV, IB, FB, AS, HK, MM, ESG, JCL, AVDM, AB, RT and JB have nothing to disclose.

Author contributions

LDP, CP and ML conceptualized the study. LDP, ES, AS, JB and MCD collected and reviewed the data on country national vaccination strategies. IB, FB, BV, PFP, MEB and RT performed a literature search of the effect of psychiatric comorbidities on COVID-19 outcomes. JB, HK and MM created the best-practice recommendations. All authors provided feedback and helped revise the manuscript.